Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58M
Nurix Therapeutics reported earnings performance that significantly exceeded market expectations. The 2026 GAAP EPS was $4.73, surpassing the anticipated $1.64, while revenue reached $673.1 million, beating the expected $193.58 million and generating an earnings surprise.
The current price is positioned near the 20-day low support line of $21.23, indicating an area with expected downward rigidity, and combined with strong earnings momentum from Aging Surprise makes a buy consideration worthwhile. However, since the moving averages are not aligned, the possibility of sell-order liquidation around the resistance level of approximately $26.35 must be thoroughly examined during any rebound.
Based on positive earnings news, we will hold positions up to the take-profit target of $26.35, but if the stock price falls below the 20-day low support level of $21.23, we will immediately cut our losses.
RSI(14) is in an oversold range at 22.3, and the moving average line is misaligned. Trading volume is at 0.95 times the 20-day average, and the recent 7-day volatility has reached -5.7%.
Although a return of 2.5% was projected, the actual result reached 12.6%, resulting in an "OVERHIT" rating. It was confirmed that the combination of severe oversold conditions with an RSI(14) of 22.3 and strong fundamental factors, specifically a $4.73 earnings surprise, drove a much stronger inflow of buying pressure than the anticipated mild rebound near the 20-day low support level ($21.23).
Through this trade, we confirmed via data that the massive earnings surprise emerging from an extreme oversold range (RSI 22.3) went beyond simply reaching the technical rebound target (breakout price $26.35); it also demonstrated the ability to accelerate the trend. For future similar periods of oversold conditions compounded by earnings surges, we will strengthen our flexibility through a phased profit-taking strategy designed to capture broader profit ranges.